Harrow, Inc. Proceeds from Notes Payable
Harrow, Inc. (HROW) reported Proceeds from Notes Payable of $49.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-10
- Harrow, Inc. proceeds from notes payable for the quarter ending 2026-06-30 was $0.00.
- Harrow, Inc. proceeds from notes payable for the quarter ending 2026-03-31 was $49.00M.
- Harrow, Inc. proceeds from notes payable for the quarter ending 2023-12-31 was $0.00.
- Harrow, Inc. proceeds from notes payable for the quarter ending 2023-09-30 was $0.00.
- Harrow, Inc. proceeds from notes payable for fiscal 2023 was $4.96M.
- Harrow, Inc. proceeds from notes payable for fiscal 2021 was $71.07M, a 3513.27% increase from fiscal 2020.
- Harrow, Inc. proceeds from notes payable for fiscal 2020 was $1.97M.
- Harrow, Inc. proceeds from notes payable for fiscal 2012 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 6 month as first filed | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 9 month as first filed | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 12 month as first filed | Proceeds from Notes Payable 155 month | Proceeds from Notes Payable 158 month | Proceeds from Notes Payable 161 month | Proceeds from Notes Payable 164 month | Proceeds from Notes Payable 167 month | Proceeds from Notes Payable 170 month | Proceeds from Notes Payable 173 month | Proceeds from Notes Payable 176 month | Proceeds from Notes Payable 182 month | Proceeds from Notes Payable 185 month | Proceeds from Notes Payable 188 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $49.00M 10-Q · filed 2026-08-10 | ||||||||||||||||
| 2026-03-31 | $49.00M 10-Q · filed 2026-05-11 | |||||||||||||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | |||||||||||||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | -$56.62M derived: sum of 3 quarters · filed 2026-03-02 | $4.96M 10-K · filed 2026-03-02 | $73.55M 10-K · filed 2024-03-19 | |||||||||||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$56.62M derived: sum of 2 quarters · filed 2024-11-14 | $4.96M 10-Q · filed 2024-11-14 | $73.55M 10-Q · filed 2023-11-13 | ||||||||||||||
| 2023-06-30 | -$56.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $4.96M 10-Q · filed 2024-08-07 | $61.59M 10-Q · filed 2023-08-09 | |||||||||||||||
| 2023-03-31 | $61.59M 10-Q · filed 2024-05-13 | |||||||||||||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $71.07M 10-K · filed 2023-03-23 | |||||||||||||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $71.07M 10-Q · filed 2022-11-14 | ||||||||||||||||
| 2021-06-30 | $71.07M 10-Q · filed 2022-08-09 | |||||||||||||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $1.97M 10-K · filed 2021-03-08 | |||||||||||||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.97M 10-Q · filed 2020-11-09 | ||||||||||||||||
| 2020-06-30 | $1.97M 10-Q · filed 2020-08-10 | |||||||||||||||||
| 2014-03-31 | $2.50M 10-Q · filed 2014-05-15 | |||||||||||||||||
| 2013-12-31 | $2.50M 10-K · filed 2014-03-28 | |||||||||||||||||
| 2013-09-30 | $2.50M 10-Q · filed 2013-11-06 | |||||||||||||||||
| 2013-06-30 | $2.50M 10-Q · filed 2013-08-14 | |||||||||||||||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 | $2.50M 10-Q · filed 2013-05-08 | ||||||||||||||||
| 2012-12-31 | $0.00 10-K · filed 2013-03-18 | $2.50M 10-K · filed 2013-03-18 | ||||||||||||||||
| 2012-09-30 | $2.50M 10-Q · filed 2012-11-14 | |||||||||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $0.00 10-Q · filed 2012-08-14 | $0.00 derived: sum of 3 quarters · filed 2013-05-08 | $0.00 derived: sum of 4 quarters · filed 2013-05-08 | $2.50M 10-Q · filed 2012-08-14 | |||||||||||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 | $0.00 derived: sum of 2 quarters · filed 2013-05-08 | $0.00 derived: sum of 3 quarters · filed 2013-05-08 | $0.00 derived: sum of 4 quarters · filed 2013-05-08 | $2.50M 10-Q · filed 2012-05-10 | |||||||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $0.00 derived: sum of 2 quarters · filed 2013-03-18 | $0.00 derived: sum of 3 quarters · filed 2013-03-18 | $0.00 10-K · filed 2013-03-18 | $2.50M 10-K · filed 2012-02-23 | |||||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $0.00 10-Q · filed 2012-02-23 | $0.00 derived: sum of 4 quarters · filed 2012-05-10 | $2.50M 10-Q · filed 2012-02-23 | |||||||||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-23 | $0.00 10-Q · filed 2012-02-23 | $0.00 derived: sum of 3 quarters · filed 2012-05-10 | $0.00 derived: sum of 4 quarters · filed 2012-05-10 | $2.50M 10-Q · filed 2012-02-23 | |||||||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2012-05-10 | $0.00 derived: sum of 3 quarters · filed 2012-05-10 | |||||||||||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $1.00M 10-K · filed 2012-02-23 | |||||||||||||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23 | $1.00M 10-Q · filed 2012-02-23 | ||||||||||||||||
| 2010-06-30 | $1.00M 10-Q · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |